Consensus statement: The role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia

BJU International

Volumn 93, Issue SUPPL. 1, 2004, Pages 27-29

  Bartsch, G ^a   Fitzpatrick, J M ^b   Schalken, J A ^c   Isaacs, J ^d   Nordling, J ^e   Roehrborn, C G ^f  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ALGORITHM; DISEASE SEVERITY; HUMAN; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; SHORT SURVEY; TREATMENT INDICATION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; CONSENSUS; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; RISK FACTORS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 1642330012     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04646.x     Document Type: Short Survey

References (20)

1. Meigs JS, Barry MJ. Natural history of benign prostatic hyperplasia. In Kirby R, McConnell JD, Fitzpatrick JM et al. eds, Textbook of Benign Prostatic Hyperplasia. Oxford, UK: Isis Medical Media Ltd, 1996: 139-48
2. Emberton M, Andriole GL, de la Rosette JJ et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003; 61: 267-73
3. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 2001; 39: 390-9
4. Boyle P. Some remarks on the epidemiology of acute urinary retention. Arch Ital Urol Nefrol Androl 1998; 70: 77-82
5. Glynn RJ, Campion EW, Bouchard GR et al. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 1985; 121: 78-90
6. Rhodes T, Girman CJ, Jacobsen SJ et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40-79 years old. J Urol 1999; 161: 1174-9
7. Roehrborn CG, McConnell J, Bonilla J et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163: 13-20
8. McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-63
9. Roehrborn CG. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 1997; 49: 548-57
10. Roehrborn CG. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology 1998; 51: 19-22
11. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53: 581-9
12. Mochtar CA, Kiemeney LALM, van Riemsdijk MM et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003; 44: 695-700
13. McConnell JD, Roehrborn CG, Slawin KM et al. Baseline measures predict the risk of benign prostatic hyperplasia clinical progression in placebo-treated patients. J Urol 2003; 169: A1287
14. Roehrborn CG, Boyle P, Bergner P et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a 4-year, randomised trial comparing finasteride versus placebo. Urology 1999; 54: 662-9
15. Roehrborn CG, Boyle P, Nickel JC. PSA is a significant predictor of objective parameters in men at risk for BPH progression. J Urol 2003; 169: A1362
16. McConnell JD and the MTOPS Steering Committee. The impact of medical therapy on the clinical progression of BPH: Results of the MTOPS Trial. J Urol 2002; 167: A1042 (updated)
17. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G on behalf of the ARIA3001, ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5 alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41
18. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405
19. Uzzo RG, Pinover WH, Horwitz EM et al. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digital rectal examination. Urology 2003; 61: 754-9
20. Brawer MK, Lin DW, Williford WO, Jones K, Lepor H. Effects of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. Prostate 1999; 39: 234-9